Dr. Mihaela Lorger  
University of Leeds, United Kingdom

HEMATOPOIETIC STEM CELL GENE THERAPY FOR BRAIN METASTASES

Several lentiviral hematopoietic stem cell (HSC) gene therapy (GT) products have been recently approved for treatment of various monogenic disorders, while lentiviral HSC-GT is less advanced when it comes to the treatment of solid tumors and metastases. My talk will focus on our recently developed pre-clinical lentiviral HSC-GT for brain metastases and glioma. I will introduce pre-clinical models of brain tumors, discuss the identification of myeloid cell-specific promoters for tumor-specific transgene expression and development of therapeutic vectors, and present preclinical efficacy data.